Exemestane
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100340

CAS#: 107868-30-4

Description: Exemestane is a synthetic androgen analogue. Exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens.

Chemical Structure

img
Exemestane
CAS# 107868-30-4
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 100340
Name: Exemestane
CAS#: 107868-30-4
Chemical Formula: C20H24O2
Exact Mass: 296.18
Molecular Weight: 296.400
Elemental Analysis: C, 81.04; H, 8.16; O, 10.80

Price and Availability

Size Price Availability Quantity
1g USD 550 Ready to ship
2g USD 950 Ready to ship
5g USD 1650 Ready to ship
10g USD 2950 Ready to ship
20g USD 5250 Ready to ship
500mg USD 350 Ready to ship
200mg USD 150 Ready to ship
Bulk inquiry

Synonym: PNU155971; PNU-155971; PNU 155971; FCE24304; FCE-24304; FCE 24304; Exemestane; US brand name: Aromasin.

IUPAC/Chemical Name: (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylene-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione.

InChi Key: BFYIZQONLCFLEV-DAELLWKTSA-N

InChi Code: InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1

SMILES Code: O=C(C=C1C(C[C@@]2([H])[C@]3([H])CC4)=C)C=C[C@]1(C)[C@@]2([H])CC[C@]3(C)C4=O

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: Exemestane (FCE24304, PNU155971) is an aromatase inhibitor, inhibits human placental and rat ovarian aromatase with IC50 of 30 nM and 40 nM, respectively.
In vitro activity: As shown in Fig. 4B, exemestane inhibited aromatase in MCF-7aro cells in a time-dependent manner. Based on previous knowledge and findings from this study, as shown in Scheme 1 , the interaction between exemestane and aromatase can be divided into three steps. Step 1 is the reversible step when exemestane binds to aromatase with a Ki of 26 nmol/L. At step 2, exemestane is converted into an intermediate, through a yet unknown process, and results in an irreversible inactivation of the enzyme. The t1/2 of this process is ∼13.9 minutes. At step 3, a degradation of aromatase by proteasome occurs after the irreversible inactivation step. We have found that in vitro incubation of exemestane with purified aromatase had no effect on aromatase protein stability. Following the exemestane treatment of MCF-7aro cells, the t1/2 of aromatase protein is reduced by 50% or more. We have determined that exemestane, at 200 nmol/L, decreases aromatase t1/2 to 12.5 hours from 28.2 hours in untreated cells. In addition, exemestane treatment did not cause significant changes of aromatase mRNA levels. Therefore, exemestane is a unique AI that can also destabilize aromatase protein. Reference: Cancer Res. 2006 Nov 1;66(21):10281-6. https://cancerres.aacrjournals.org/content/66/21/10281.long
In vivo activity: The effect of EXE on liver injury and fibrosis were assessed in two hepatic fibrosis rat models, which were induced by either carbon tetrachloride (CCl4) or bile duct ligation (BDL). The influence of EXE treatment on activation and proliferation of primary rat hepatic stellate cells (HSCs) was observed in vitro. The results showed that EXE attenuated the liver fibrosis by decreasing the collagen deposition and α-SMA expression in vivo and inhibited the activation and proliferation of primary rat HSCs in vitro. Additionally, EXE promoted the secretion of antifibrotic and anti-inflammatory cytokine IL-10 in vivo and in HSC-T6 culture media. In conclusion, our findings reveal a new function of EXE on hepatic fibrosis and prompted its latent application in liver fibrotic-related disease. Reference: J Immunol Res. 2017;2017:3072745. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29464186/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 54.0 182.19
Ethanol 21.0 70.85

Preparing Stock Solutions

The following data is based on the product molecular weight 296.400000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Wang X, Chen S. Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. Cancer Res. 2006 Nov 1;66(21):10281-6. doi: 10.1158/0008-5472.CAN-06-2134. PMID: 17079446. 2. Jayapal JJ, Dhanaraj S. Exemestane loaded alginate nanoparticles for cancer treatment: Formulation and in vitro evaluation. Int J Biol Macromol. 2017 Dec;105(Pt 1):416-421. doi: 10.1016/j.ijbiomac.2017.07.064. Epub 2017 Jul 13. PMID: 28711612. 3. Wang YH, Li RK, Fu Y, Li J, Yang XM, Zhang YL, Zhu L, Yang Q, Gu JR, Xing X, Zhang ZG. Exemestane Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells and Promoting the Secretion of Interleukin 10. J Immunol Res. 2017;2017:3072745. doi: 10.1155/2017/3072745. Epub 2017 Dec 10. PMID: 29464186; PMCID: PMC5804406.
In vitro protocol: 1. Wang X, Chen S. Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. Cancer Res. 2006 Nov 1;66(21):10281-6. doi: 10.1158/0008-5472.CAN-06-2134. PMID: 17079446. 2. Jayapal JJ, Dhanaraj S. Exemestane loaded alginate nanoparticles for cancer treatment: Formulation and in vitro evaluation. Int J Biol Macromol. 2017 Dec;105(Pt 1):416-421. doi: 10.1016/j.ijbiomac.2017.07.064. Epub 2017 Jul 13. PMID: 28711612.
In vivo protocol: 1. Wang YH, Li RK, Fu Y, Li J, Yang XM, Zhang YL, Zhu L, Yang Q, Gu JR, Xing X, Zhang ZG. Exemestane Attenuates Hepatic Fibrosis in Rats by Inhibiting Activation of Hepatic Stellate Cells and Promoting the Secretion of Interleukin 10. J Immunol Res. 2017;2017:3072745. doi: 10.1155/2017/3072745. Epub 2017 Dec 10. PMID: 29464186; PMCID: PMC5804406.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gilabert M, Launay S, Gonçalves A. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option]. Bull Cancer. 2014 Mar;101(3):325-33. doi: 10.1684/bdc.2014.1910. Review. French. PubMed PMID: 24691195. 2: Van Asten K, Neven P, Lintermans A, Wildiers H, Paridaens R. Aromatase inhibitors in the breast cancer clinic: focus on exemestane. Endocr Relat Cancer. 2014 Jan 16;21(1):R31-49. doi: 10.1530/ERC-13-0269. Print 2014 Feb. Review. PubMed PMID: 24434719. 3: Dunn BK, Cazzaniga M, DeCensi A. Exemestane: one part of the chemopreventive spectrum for ER-positive breast cancer. Breast. 2013 Jun;22(3):225-37. doi: 10.1016/j.breast.2013.02.015. Epub 2013 Mar 25. Review. PubMed PMID: 23535509. 4: Dhillon S. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs. 2013 Apr;73(5):475-85. doi: 10.1007/s40265-013-0034-2. Review. PubMed PMID: 23529824. 5: Decensi A, Dunn BK, Puntoni M, Gennari A, Ford LG. Exemestane for breast cancer prevention: a critical shift? Cancer Discov. 2012 Jan;2(1):25-40. doi: 10.1158/2159-8290.CD-11-0248. Review. PubMed PMID: 22585166; PubMed Central PMCID: PMC3354700. 6: Santoro S, Santini M, Pepe C, Tognetti E, Cortelazzi C, Ficarelli E, De Panfilis G. Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol. 2011 May;25(5):596-8. doi: 10.1111/j.1468-3083.2010.03803.x. Review. PubMed PMID: 21492245. 7: Lintermans A, Neven P, Paridaens R. Drug safety evaluation of exemestane. Expert Opin Drug Saf. 2011 May;10(3):473-87. doi: 10.1517/14740338.2011.567264. Epub 2011 Mar 24. Review. PubMed PMID: 21428848. 8: Bertelli G, Gangadhara S. Exemestane in postmenopausal women with early or advanced breast cancer: a review. Expert Opin Pharmacother. 2010 Aug;11(11):1933-42. doi: 10.1517/14656566.2010.495945. Review. PubMed PMID: 20569090. 9: Macpherson IR, Lindsay C, Canney P. Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer (Dove Med Press). 2010 Oct 14;2:59-70. doi: 10.2147/BCTT.S11835. Review. PubMed PMID: 24367167; PubMed Central PMCID: PMC3846455. 10: Glück S. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer. Am J Clin Oncol. 2010 Jun;33(3):314-9. doi: 10.1097/COC.0b013e31819fdf9b. Review. PubMed PMID: 19730353.